(AOF) – Poxel announces the publication of its 2023 annual results “at the end of April 2024” when it was initially scheduled for April 9. The biotech specialist in serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH), cites “the expected conclusion of a transaction by the end of April”. Having made significant progress in its search for additional financing, the company aims, by the end of April, to conclude an agreement relating to the monetization of royalties from sales of its product Twymeeg (Imeglimin) in Japan.
Poxel expects that its financial resources will be sufficient to maintain its operations “until the finalization of this monetization transaction”. The company will communicate its new financial calendar for the month of April 2024, once finalized.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.